In a cohort of 85 biopsied patients, it has been found that a lower expression of PPARα correlated with the severity of liver disease, suggesting that it may represent a possible pharmacological target in NASH treatment [109]. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.